Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27213513 | 0.95 | MAPT (0.46) | MAPTALDH1A1NPC1RAB9AGMNN | |
| SCHEMBL31292023 | 0.89 | ALDH1A1 (0.46) | MAPTALDH1A1CYP3A4SMN1; SMN2HSD17B10 | |
| SCHEMBL30695905 | 0.86 | MAPT (0.41) | MAPTALDH1A1NPC1RAB9AGMNN | |
| SCHEMBL17893665 | 0.86 | MAPT (0.41) | MAPTALDH1A1NPC1RAB9AGMNN | |
| SCHEMBL4427069 | 0.84 | CYP3A4 (0.48) | MAPTALDH1A1NPC1RAB9AGMNN | |
| SCHEMBL6846413 | 0.84 | ALDH1A1 (0.44) | MAPTALDH1A1NPC1RAB9AGMNN | |
| SCHEMBL15934299 | 0.84 | MAPT (0.39) | MAPTALDH1A1NPC1RAB9AGMNN | |
| SCHEMBL10978352 | 0.84 | ALDH1A1 (0.50) | MAPTALDH1A1NPC1RAB9AGMNN | |
| SCHEMBL30105030 | 0.84 | CYP3A4 (0.48) | MAPTALDH1A1NPC1RAB9AGMNN | |
| SCHEMBL12397903 | 0.84 | MAPT (0.39) | MAPTALDH1A1NPC1RAB9AGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-01-29 | — | — | US | disclosed |
| US-10065966-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2018-09-04 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| US-7659416-B2 | Monomolecular conductive complex, conductive self-assembled film and assembly of electrode composed of metal and semiconductor making use of the same | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20090312432-A1 | FLUOROSURFACTANTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090264525-A1 | FLUOROSURFACTANTS | MERCK PATENT GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090197201-A1 | FLUOROSURFACTANTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20090036698-A1 | Monomolecular Conductive Complex, Conductive Self-Assembled Film and Assembly of Electrode Composed of Metal and Semiconductor Making Use of the Same | TOKYO INSTITUTE OF TECHNOLOGY | 2009-02-05 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1862453-A1 | MONOMOLECULAR CONDUCTIVE COMPLEX, CONDUCTIVE SELF-ASSEMBLED FILM AND ASSEMBLY OF ELECTRODE COMPOSED OF METAL AND SEMICONDUCTOR MAKING USE OF THE SAME | Tokyo Institute of Technology (JP) | 2007-12-05 | — | — | EP | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | MAPT 4190/4885ALDH1A1 3719/4885NPC1 1614/4885 |
| US-20090036698-A1 | Monomolecular Conductive Complex, Conductive Self-Assembled Film and Assembly of Electrode Composed of Metal and Semiconductor Making Use of the Same | CNTN1, GAP43, AP3M1 | MAPT 1911/4885ALDH1A1 3087/4885NPC1 4609/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAPT 1888/4885ALDH1A1 684/4885NPC1 48/4885 |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | MAPT 4190/4885ALDH1A1 3719/4885NPC1 1614/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MAPT 4299/4885ALDH1A1 412/4885NPC1 3130/4885 |
| US-20090312432-A1 | FLUOROSURFACTANTS | SGMS2, FASN, SGMS1 | MAPT 4870/4885ALDH1A1 2479/4885NPC1 493/4885 |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | MAPT 1888/4885ALDH1A1 684/4885NPC1 48/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | MAPT 2455/4885ALDH1A1 3786/4885NPC1 4611/4885 |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | MAPT 1888/4885ALDH1A1 684/4885NPC1 48/4885 |
| US-20090264525-A1 | FLUOROSURFACTANTS | FASN, FFAR3, SGMS2 | MAPT 4853/4885ALDH1A1 2925/4885NPC1 383/4885 |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAPT 1888/4885ALDH1A1 684/4885NPC1 48/4885 |
| US-10065966-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CDK2, PDXK, MAP4K2 | MAPT 2952/4885ALDH1A1 3398/4885NPC1 4456/4885 |
| US-20090197201-A1 | FLUOROSURFACTANTS | CBR3, SCO2, FPR3 | MAPT 4841/4885ALDH1A1 3874/4885NPC1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.